{
    "id": "15dd0555-b33f-4f56-94d3-0f4ce888df01",
    "indications": {
        "text": "sunitinib malate capsule kinase inhibitor indicated : treatment adult patients gastrointestinal stromal tumor ( gist ) disease progression intolerance imatinib mesylate . ( 1.1 ) treatment adult patients advanced renal cell carcinoma ( rcc ) . ( 1.2 ) adjuvant treatment adult patients high risk recurrent rcc following nephrectomy . ( 1.3 ) treatment progressive , well-differentiated pancreatic neuroendocrine tumors ( pnet ) adult patients unresectable locally advanced metastatic disease . ( 1.4 )",
        "doid_entities": [
            {
                "text": "gastrointestinal stromal tumor (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "gist advanced rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) . ( 2.1 ) adjuvant treatment rcc : recommended 50 mg orally daily first 4 weeks 6-week cycle ( schedule 4/2 ) maximum 9 cycles . ( 2.2 ) pnet : recommended 37.5 mg orally daily . ( 2.3 )",
        "doid_entities": [
            {
                "text": "gist (DOID:9253)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9253"
            },
            {
                "text": "rcc (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sunitinib malate 12.5 mg capsules supplied size \u201c 4 \u201d hard gelatin capsules orange opaque body imprinted \u201c 6 \u201d orange opaque cap imprinted \u201c multiple sclerosis \u201d white ink : bottles 28 capsules : ndc 72205-116-28 sunitinib malate 25 mg capsules supplied size \u201c 3 \u201d hard gelatin capsules orange opaque body imprinted \u201c 7 \u201d caramel opaque cap imprinted \u201c multiple sclerosis \u201d white ink : bottles 28 capsules : ndc 72205-117-28 sunitinib malate 37.5 mg capsules supplied size \u201c 3 \u201d hard gelatin capsules yellow opaque body imprinted \u201c 8 \u201d yellow opaque cap imprinted \u201c multiple sclerosis \u201d black ink : bottles 28 capsules : ndc 72205-118-28 sunitinib malate 50 mg capsules supplied size \u201c 2 \u201d hard gelatin capsules caramel opaque body imprinted \u201c 9 \u201d caramel opaque cap imprinted \u201c multiple sclerosis \u201d white ink : bottles 28 capsules : ndc 72205-119-28 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "SUNITINIB MALATE",
            "code": "LVX8N1UT73",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232546"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        }
    ],
    "organization": "Novadoz Pharmaceuticals LLC",
    "name": "Sunitinib Malate",
    "effectiveTime": "20250210",
    "indications_original": "Sunitinib malate capsule\u00a0is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )",
    "contraindications_original": "GIST and Advanced RCC: The recommended dosage is 50 mg orally once\u00a0daily for the first 4 weeks of each 6-week cycle (Schedule 4/2). ( 2.1 ) Adjuvant Treatment of RCC: The recommended dosage is 50 mg orally once daily\u00a0for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles. ( 2.2 ) pNET: The recommended dosage is 37.5 mg orally once daily.\u00a0( 2.3 )",
    "warningsAndPrecautions_original": "Sunitinib malate 12.5 mg capsules are supplied as Size \u201c4\u201d hard gelatin capsules with orange opaque body imprinted with \u201c6\u201d and orange opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-116-28 Sunitinib malate 25 mg capsules are supplied as Size \u201c3\u201d hard gelatin capsules with orange opaque body imprinted with \u201c7\u201d and caramel opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-117-28 Sunitinib malate 37.5 mg capsules are supplied as Size \u201c3\u201d hard gelatin capsules with yellow opaque body imprinted with \u201c8\u201d and yellow opaque cap imprinted with \u201cMS\u201d in black ink: Bottles of 28 capsules: NDC 72205-118-28 Sunitinib malate 50 mg capsules are supplied as Size \u201c2\u201d hard gelatin capsules with caramel opaque body imprinted with \u201c9\u201d and caramel opaque cap imprinted with \u201cMS\u201d in white ink: Bottles of 28 capsules: NDC 72205-119-28 Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Sunitinib Malate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_232546"
        }
    ]
}